SinoMAKS—protocol of a randomised controlled trial to evaluate the Chinese version of the non-pharmacological, multimodal MAKS intervention for people with mild to moderate dementia in Chinese nursing homes

BMJ Open, Journal Year: 2025, Volume and Issue: 15(4), P. e093618 - e093618

Published: April 1, 2025

The prevalence of dementia is increasing, both worldwide and in China. This disease associated with numerous restrictions for those affected but also caregivers society. Due to the limited effectiveness pharmacological interventions, more research on non-pharmacological interventions needed. For multimodal MAKS (M: motor training, A: activities daily living K: cognitive S: social-communicative setting) intervention, positive effects cognition, living, occurrence behavioural psychological symptoms were identified two randomised controlled trials different settings Germany. Thus, German intervention was culturally adapted China will now be tested its efficacy Chinese nursing homes a trial. Participants residents Shenyang, Nanjing Dalian, fulfilling ICD-10 criteria Alzheimer's dementia, psychometric mild moderate (MMSE 10-23) none exclusion criteria. With n=200, an effect size Cohen's d=0.45 power 1-β = 0.80 can detected. Screening data collection at baseline, t6 t12 conducted via face-to-face contact by proxy raters (i.e., trained staff not involved intervention) master students as external testers performance tests cognition living. randomly allocated or control group. SinoMAKS version least three times week six months therapists. group receive care usual 12 after baseline. treatment phase follow-ups In open phase, from t12, are free offer residents. line international guidelines, primary population analysis intention-to-treat sample. Global (measured Addenbrooke's Cognitive Examination-III) outcome. hypotheses analysed using multiple linear regression outcome variables dependent variables. All procedures approved Ethics Committee Medical Faculty Friedrich-Alexander-Universität Erlangen-Nürnberg (Ref. 24-162-B) University [2024]181). Written informed consent obtained all participants or-if applicable-their legal representatives. Results published peer-reviewed scientific journals conference presentations. ISRCTN10262531.

Language: Английский

---

The efficacy and safety of anti-amyloid monoclonal antibody versus acetylcholinesterase inhibitor with an in-depth analysis across genotypes and disease stages: a systematic review and meta-analysis

The Journal of Prevention of Alzheimer s Disease, Journal Year: 2025, Volume and Issue: unknown, P. 100195 - 100195

Published: May 1, 2025

To date, studies have not compared the efficacy and safety of monoclonal antibodies (mABs) with acetylcholinesterase inhibitors (AChEIs). Five electronic databases were systemic searched from inception to 10 November 2024 for double-blinded randomized controlled trial (RCT) patients diagnosed MCI or mild AD treated mABs AChEIs at least 6 months. The primary outcome was change in cognitive function, measured by Alzheimer's Disease Assessment Scale-cognitive subscale 14-item (ADAS-Cog) Clinical Dementia Rating Scale-Sum Boxes (CDR-SOB). secondary outcomes acceptability, tolerability, serious adverse events (SAE), all -cause mortality. For mABs, amyloid-related imaging abnormalities-edema (ARIA-E), abnormalities-hemorrhage (ARIA-H) also assessed. Subgroup analyses included (i) versus AD; (ii) without concomitant medications; (iii) Apolipoprotein E (ApoE4) carriers non-carriers. Data pooled using a random effects model within Bayesian framework. There 8010 participants (mean age: 71.5 years) across seven mAB trials, 4993 age:70.7 nine AChEI trials. When placebo, only AChEIs, associated slower progression decline on CDR-SOB difference -0.41 (95 % credible interval -0.61 -0.22); minimally important (MID) -1) ADAS-Cog (-1.35 (-2.36 -0.36), MID -2); however, these benefits did reach two measurements. Besides, (-0.30 (-0.60 -0.001)) than although differ outcomes, including SAE, all-cause Further analysis indicated that their disease stage, medications, APOE4 carrier status. However, homozygotes 5.53-fold (2.48 13.07) increased odds developing ARIA-E Finally, lecanemab demonstrated relatively better more favorable profile aducanumab donanemab. AChEIs; this effect MID. incidence status indicative treatment efficacy.

Language: Английский

---

Lecanemab in Alzheimer’s disease: a profile of its use

Drugs & Therapy Perspectives, Journal Year: 2024, Volume and Issue: 40(10), P. 393 - 400

Published: Sept. 20, 2024

Language: Английский

---

Survival After the Diagnosis of Mild‐to‐Moderate Alzheimer's Disease Dementia: A 15‐Year National Cohort Study in Taiwan

International Journal of Geriatric Psychiatry, Journal Year: 2024, Volume and Issue: 39(9)

Published: Sept. 1, 2024

Pharmacological and non-pharmacological interventions are mostly designed for patients with early Alzheimer's disease (AD) dementia. Long-term case management planning the remainder of life disability require an estimation survival duration.

Language: Английский

---

Individualised computerised cognitive training (iCCT) for community-dwelling people with mild cognitive impairment (MCI): results on cognition in the 6-month intervention period of a randomised controlled trial (MCI-CCT study)

BMC Medicine, Journal Year: 2024, Volume and Issue: 22(1)

Published: Oct. 15, 2024

Computerised cognitive training (CCT) can improve the abilities of people with mild impairment (MCI), especially when CCT contains a learning system, which is type machine (ML) that automatically selects exercises at difficulty corresponds to person's peak performance and thus enables individualised training.

Language: Английский

---